Avid Bioservices (CDMO) Misses Q4 EPS by 1c; guides below views

Avid Bioservices (NASDAQ: CDMO) reported Q4 EPS of $0.00, $0.01 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $39.8 million versus the consensus estimate of $38.91 million.

GUIDANCE:

Avid Bioservices sees FY2024 revenue of $145-165 million, versus the consensus of $181.27 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
• Investing.com’s stocks of the week